Jan 22 (Reuters) - Moderna ( MRNA ) does not plan to
invest in new late-stage vaccine trials because of growing
opposition to immunizations from U.S. officials, CEO Stephane
Bancel said in an interview with Bloomberg TV on Thursday.
(Reporting by Gnaneshwar Rajan in Bengaluru; Editing by Anil
D'Silva)